Glycoproteomics-based Liquid-biopsy LDT Development Service for Non-Alcoholic SteatoHepatitis (NASH)

Aberrant Glycosylation in NASH

The fatty liver disease progresses through a series of stages, starting with fat accumulation and inflammation, progressing to NASH, followed by fibrosis and cirrhosis, and potentially culminating in hepatocellular carcinoma (HCC). Glycoproteins hold pivotal roles across various inflammation processes including NASH. Changes with alternative glycosylation sites and oligosaccharide structures can serve as good biomarkers for NASH.

Fig.1 Aberrant glycosylation in NASH.

Glycoproteomics-based Liquid-biopsy LDT Development for NASH at Creative Biolabs

Fig.2 Workflow of lectin affinity chromatography.¹

At Creative Biolabs, we fully comprehend the intricate nature of glycan structures, attachment sites, and abundance variations, to effectively address these complexities, we have developed a comprehensive glycoproteomics-based liquid-biopsy LDT development platform with tailored enrichment strategies.

In lectin affinity chromatography, we harness the specificity of various lectins to selectively enrich specific glycopeptides that possess particular glycan modifications. By employing these lectins, the glycopeptides of interest can be captured and concentrated from complex samples. Additionally, we have advanced enrichment capabilities by incorporating multi-lectin affinity columns, these specialized columns are engineered to encompass a mixture of diverse lectins, allowing for the comprehensive enrichment of a wide spectrum of glycoproteins present in samples.

Furthermore, the utilization of tandem mass spectrometry (MS/MS) in our LDTs offers a wealth of comprehensive details encompassing glycan compositions and structures through strategic fragmentation methods. Augmented by cutting-edge software tools for data analysis and glycoprotein interpretation, we possess the capability to analyze extensive sample sets effectively.

Highlights

Fig.3 Highlights of our LDT services.

Published Data

Technology: Glycoproteomic analysis

Journal: Scientific Reports

Published: 2020

Results: Serum AAT-A3F levels are strongly increased with fibrosis, and pathological inflammation, and may be useful for non-invasive diagnosis of NASH from the early stages of fibrosis.

Fig.4 Diagnostic performance of AAT-A3F for NASH.²

Creative Biolabs has effectively ventured into pioneering and adaptable glycoproteomic analysis platforms. We proudly extend all-encompassing glycoproteomics-based liquid-biopsy LDT services tailored for NASH. Please feel free to contact us, and we will be thrilled to provide you with comprehensive information and support.

References

1. Hashim, Onn Haji, et al. "Lectins: an effective tool for screening of potential cancer biomarkers." PeerJ 5 (2017): e3784.
2. Ogawa, Koji, et al. "Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: A novel glycobiomarker for non-alcoholic steatohepatitis." Scientific reports 10.1 (2020): 321.

Related Services:

1. NSCLC
2. Pancreas Carcinoma
3. Renal Cell Carcinoma
4. Nasopharyngeal Carcinoma
5. HCC
6. Advanced Adenoma
7. Colorectal Cancer
8. Prostate Cancer